Ekso Bionics FY2025 EPS Forecast Raised by HC Wainwright

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Equities researchers at HC Wainwright raised their FY2025 EPS estimates for shares of Ekso Bionics in a note issued to investors on Wednesday, December 31st. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.87) per share for the year, up from their prior forecast of ($0.92). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.10) EPS.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Tuesday, October 28th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.45. The business had revenue of $4.23 million for the quarter, compared to analyst estimates of $4.16 million. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%.

A number of other research firms have also weighed in on EKSO. Wall Street Zen raised Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Ekso Bionics presently has a consensus rating of “Hold” and an average target price of $10.50.

Ekso Bionics Price Performance

EKSO stock opened at $8.55 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66. The firm has a 50 day moving average price of $5.18 and a 200-day moving average price of $4.42. Ekso Bionics has a 52-week low of $2.73 and a 52-week high of $14.97. The firm has a market capitalization of $22.43 million, a price-to-earnings ratio of -1.51 and a beta of 0.71.

Insider Buying and Selling

In other Ekso Bionics news, CFO Jerome Wong sold 11,288 shares of Ekso Bionics stock in a transaction on Monday, November 10th. The stock was sold at an average price of $4.80, for a total value of $54,182.40. Following the completion of the sale, the chief financial officer owned 26,009 shares of the company’s stock, valued at approximately $124,843.20. This trade represents a 30.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Scott G. Davis sold 23,315 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $4.80, for a total value of $111,912.00. Following the completion of the transaction, the chief executive officer owned 78,777 shares of the company’s stock, valued at $378,129.60. This represents a 22.84% decrease in their position. The SEC filing for this sale provides additional information. 6.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Ekso Bionics

Institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in Ekso Bionics in the 3rd quarter worth about $57,000. Shay Capital LLC bought a new stake in shares of Ekso Bionics in the third quarter worth approximately $67,000. Citadel Advisors LLC purchased a new position in shares of Ekso Bionics during the third quarter valued at approximately $198,000. Finally, Consolidated Portfolio Review Corp bought a new position in Ekso Bionics during the third quarter valued at approximately $333,000. 6.42% of the stock is owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.